Sweden · Delayed Price · Currency is SEK BICO Group AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 11% organic growth, led by desktop instrument sales and strong performance in genomics and OEM segments, despite currency headwinds and weak U.S. academia. Restructuring and cost control improved adjusted EBITDA, while new bond issuance and property divestment strengthened liquidity.
Fiscal Year 2025
-
2025 ended with strong Lab Automation growth and improved cash position, despite overall negative organic sales growth and challenging market conditions. New capital was raised to support future growth, and product launches like GoSimple received strong interest.
-
Q3 2025 delivered 12% organic sales growth and improved margins, driven by strong lab automation demand and major commercial wins. Divestments strengthened the cash position, while impairments impacted EBIT but not cash flow. Positive outlook with stable R&D and cost control.
-
Q2 2025 saw negative organic growth and profitability challenges, mainly due to project delays in Lab Automation, while Life Science Solutions delivered flat sales. The divestment of MatTek and Visikol strengthened the balance sheet, and operational improvements are underway to address project execution and margin pressures.
-
Q1 2025 saw a 19% organic sales decline, but life science solutions and bioprinting grew, offsetting lab automation weakness. The divestment of MatTek and Visikol will move the group to a net cash position in Q2 2025, with strategic focus shifting to pharma and biotech.
Fiscal Year 2024
-
Q4 2024 saw stable sales, significant margin improvement, and strong cash flow, with all business areas achieving double-digit EBITDA margins. The company divested non-core assets, reduced debt, and is well-positioned for gradual market recovery, focusing on commercial and R&D initiatives.
-
Q3 2024 saw weak instrument sales and a net loss, but all business areas remained profitable with improved gross margin. Key actions included divesting Nanoscribe, repurchasing convertible bonds, and rightsizing CELLINK, with a continued focus on operational excellence and debt reduction.
-
BICO unveiled its BICO 2.0 strategy, focusing on lab automation, integrated workflows, and recurring revenue, with new business areas and a realigned executive team. Lab Automation sales surged 40% YoY, and financial targets were reiterated despite market headwinds. AI-driven automation and strategic partnerships are central to future growth.
-
Q2 2024 saw SEK 534 million in sales with -2% organic growth, all segments EBITDA positive, and improved gross margin. Market remains volatile, especially in Asia, but cost control and strategic hires support ongoing transformation.